Bleeds Happen1 Treat fast with NovoSeven®1,2 Haemostatic response with rFVIIa by age and time to treatment 2
Haemostatic response with NovoSeven® patients in SMART-7™ *†‡ 2
80 60
(11) 96,5 (307)
%
≥4 h
> 1-4 h 93,1 (94)
%
(1) (6)
87,3 (55)
%
40 20 0
Total (n=318)
Total (n=101)
Total (n=63)
(2) (6)
100 Percentage of effectiveness
Percentage of effectiveness
100
≤1h
80 60
All bleeds
Joint bleeds
(3)
94,6 % (23) (456)
93 % (262)
Muscle bleeds (2) (18)
96,4 % (106)
40 20 0
Total (n=482)
Total (n=282)
(1) (3) Effective Partially effective Ineffective
Total (n=110)
*SMART-7™=study monitoring antibodies against room-temperature–stable factor 7. The SMART-7™ study was a prospective, observational, single-arm, multi-centre, multi-national study investigating the safety and effectiveness of room-temperature–stable NovoSeven®3 in people with haemophilia A or B with inhibitors in a real-world setting.2 **CHwI=congenital haemophilia with 2 ‡ Bleeds treated inhibitors. † Sub-analysis of SMART-7™ assessed haemostatic response to NovoSeven® 2 For full prescribing information, refer to the Professional Information approved by the Medicines Regulatory Authority. Text revision date by SAHPRA: 2023/07/24. Reg. No.: NovoSeven® 1 mg: 44/8.1/0550, NovoSeven® 2 mg: 44/8.1/0551, NovoSeven® 5 mg: 44/8.1/0552. References: 1) Maahs J, et al. Journal of Blood Medicine 2014;5:153-156. 2) Demartis F, et al. TH Open 2017;1:e130-e138. 3) NovoSeven® approved professional information. Applicant Address: South Africa. Tel: 011 202 0500 Fax: 011 807 7989. 2023_10 Novo Nordisk (Pty) Ltd, 1959/000833/07 ZA23NS00028
Scan for further information. Information is intended for Health Care Professionals only. Not to be distributed to patients.
WFH 2024 WORLD CONGRESS APRIL 21-24 | MADRID, SPAIN REGISTER NOW! wfh.org/congress
ORGANIZED BY: World Federation of Hemophilia HOSTED BY:
t -PDBMMZ NBOVGBDUVSFE BOE SFBEJMZ BWBJMBCMF t /P SFGSJHFSBUJPO SFRVJSFE TUPSFE BU PS CFMPX 0 C) t $POUBJOT BMM SFRVJSFE DPNQPOFOUT GPS SFDPOTUJUVUJPO BOE BENJOJTUSBUJPO
t $POUJOVFE QIBSNBDPWJHJMBODF BOE NPOJUPSJOH BDUJWJUJFT JOEJDBUF UIBU Haemosolvate ® Factor VIII BOE Haemosolvex ® Factor IX SFNBJO IJHI RVBMJUZ TBGF BOE FGmDBDJPVT QSPEVDUT GPS UIFJS SFHJTUFSFE JOEJDBUJPOT
3&'&3&/$&4 )BFNPTPMWBUF ® 'BDUPS 7*** 1FSJPEJD 4BGFUZ 6QEBUF 3FQPSU '7***@
)BFNPTPMWFY ® 'BDUPS *9 1FSJPEJD 4BGFUZ 6QEBUF 3FQPSU '*9@
4 Haemosolvate ® Factor VIII 300 IU, 500 IU MZPQIJMJTFE QPXEFS GPS *7 JOKFDUJPO )VNBO 'BDUPS 7*** $PODFOUSBUF 1BDL TJ[FT BWBJMBCMF *6 *6 Y *6 3FH /P hT *6 : *6 'PS GVMM QSFTDSJCJOH JOGPSNBUJPO SFGFS UP UIF 1SPGFTTJPOBM *OGPSNBUJPO 1* BQQSPWFE CZ UIF NFEJDJOFT SFHVMBUPSZ BVUIPSJUZ %BUF PG QVCMJDBUJPO PG 1* 1* WFSTJPO OVNCFS 1
4 Haemosolvex ® Factor IX MZPQIJMJTFE QPXEFS GPS *7 JOKFDUJPO )VNBO 'BDUPS *9 DPNQMFY QSPUISPNCJO DPNQMFY 3FH /P 8 'PS GVMM QSFTDSJCJOH JOGPSNBUJPO SFGFS UP UIF 1SPGFTTJPOBM *OGPSNBUJPO 1* BQQSPWFE CZ UIF NFEJDJOFT SFHVMBUPSZ BVUIPSJUZ %BUF PG QVCMJDBUJPO PG 1* 1* WFSTJPO OVNCFS 1 /BNF BOE CVTJOFTT BEESFTT PG UIF IPMEFS PG UIF DFSUJmDBUF PG SFHJTUSBUJPO /BUJPOBM #JPQSPEVDUT *OTUJUVUF /1$ $PNQBOZ 3FH /P /10 3FH /P /10 &EFO 3PBE 1JOFUPXO 4PVUI "GSJDB 5FMFQIPOF XXX OCJTB PSH [B 130 #
IT’S A FEELING IF YOU KNOW YOU KNOW
HEMLIBRA® Abbreviated BSS: S4 Hemlibra®: Emicizumab 30 mg/1 mL; 60 mg/0,4 mL; 105 mg/0,7 mL; 150 mg/1 mL per vial; solution for injection. South Africa: 53/30.1/0071/2/3/4; Namibia: NS2 19/30/0033/4/5/6; Zimbabwe PP 2019/10.7/5815/4/3/2; Botswana S2 BOT2103738/7/6/0; Zambia POM ZAMRA-HM-23-15/17/25/35. For full prescribing information, refer to the professional information approved by the Medicines Regulatory Authority. M-ZA-00000947 - 6/2025 Roche Products (Pty) Ltd, P O Box 1469, Halfway House, 1685. Tel: 011 504 4746 or Toll-free on REAL (Roche Ethical Assistance Line): 0800 21 21 25. www.roche.co.za M-ZA-00002018 - 10/2025